首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MIP5 |
| Uniprot No | Q16663 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 46-113aa |
| 氨基酸序列 | SFHFAADCCT SYISQSIPCS LMKSYFETSS ECSKPGVIFL TKKGRQVCAK PSGPGVQDCM KKLKPYSI |
| 预测分子量 | 7.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MIP5(CCL15)重组蛋白研究的模拟参考文献示例。由于无法提供真实文献，以下内容基于常见研究主题构建，建议通过学术数据库(如PubMed、Google Scholar)检索具体文献：
---
1. **文献名称**：*Expression and Functional Characterization of Recombinant Human CCL15/MIP5 in a Baculovirus System*
**作者**：Zhang L, et al.
**摘要**：本研究利用杆状病毒-昆虫细胞系统成功表达并纯化了重组人CCL15/MIP5蛋白。通过体外趋化实验证实，该重组蛋白对单核细胞和中性粒细胞具有显著趋化活性，并验证了其通过CCR1受体介导的信号通路。
2. **文献名称**：*Role of Recombinant MIP5 in Tumor-Associated Macrophage Recruitment*
**作者**：Kim S, et al.
**摘要**：通过大肠杆菌表达系统制备重组MIP5蛋白，发现其在肿瘤微环境中促进巨噬细胞迁移和浸润，可能通过激活PI3K/AKT通路增强肿瘤相关炎症反应，为癌症免疫治疗提供潜在靶点。
3. **文献名称**：*Structural Analysis and Receptor Binding Specificity of Engineered CCL15 Variants*
**作者**：Wang Y, et al.
**摘要**：采用哺乳动物细胞表达体系获得高纯度重组CCL15蛋白，通过点突变和晶体结构解析，揭示了其与受体CCR3结合的關鍵结构域，为开发基于MIP5的抗炎药物奠定基础。
4. **文献名称**：*Optimization of Recombinant MIP5 Production in Pichia pastoris for Clinical Applications*
**作者**：Garcia-Ruiz E, et al.
**摘要**：通过毕赤酵母系统优化MIP5重组蛋白的分泌表达条件，显著提高产量并保留生物活性。该研究为大规模生产适用于临床试验的MIP5提供了可行性方案。
---
**备注**：以上文献信息为模拟内容，实际研究请参考权威数据库。检索时可使用关键词 **"CCL15"、"MIP5"、"recombinant protein"、"chemokine"** 等组合进行精准查询。
MIP-5 (Macrophage Inflammatory Protein-5), also known as CCL15 or HCC-2. is a chemokine belonging to the CC subfamily. It is primarily involved in immune regulation, inflammation, and cellular recruitment. Structurally, MIP-5 contains a conserved N-terminal region and a CC motif critical for receptor binding and signaling. The protein is encoded by the CCL15 gene in humans and is expressed in various tissues, including the liver, spleen, and lymph nodes, with elevated levels observed during inflammatory responses.
MIP-5 functions as a chemoattractant for immune cells such as monocytes, lymphocytes, and eosinophils by interacting with chemokine receptors CCR1 and CCR3. This interaction activates downstream signaling pathways, including MAPK and PI3K, which mediate cell migration and immune activation. Studies suggest its role in chronic inflammatory diseases, such as rheumatoid arthritis, asthma, and inflammatory bowel disease, where excessive leukocyte infiltration contributes to tissue damage. Additionally, MIP-5 has been implicated in tumor microenvironments, potentially facilitating cancer progression by modulating immune evasion and angiogenesis.
Recombinant MIP-5 is produced using expression systems like E. coli or mammalian cells, enabling controlled studies of its biological activities. The recombinant form retains native structure and function, allowing researchers to investigate its interactions with receptors and therapeutic inhibitors. Its applications span drug discovery, biomarker research, and mechanistic studies in immunopathology. Despite progress, the precise regulatory mechanisms and therapeutic potential of MIP-5 in disease contexts remain under active exploration, highlighting its significance as a target for immune-modulating therapies.
×
